TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Muscle Insulin Sensitivity-M Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional rating scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Volume of distribution of [11C]GSK1034702
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Knee injury and Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sympathetic Nerve Activity - cold pressor test response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of phenol recovered in lavage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NYHA (New York Heart Association) evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24 hour average pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Somatic complaints
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Signs of improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney Allograft Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Heart Rate Variabilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: % time in sleep stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: arousals and awakenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: maximum percentage fall in FEV1 after exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC for the FEV1 values over the 20-min period from exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy (percentage of unablated tissue in the ablation zone)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Epidemiology and outcomes of TMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Vasopressor Index (CVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of prescribed Tylenol with Codeine utilized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Patients Reporting Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Reporting Treatment-Related, Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Reporting Treatment-Emergent Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patient Discontinuations Due to Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Hospitalized days - length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Emergency Room visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients with 50% post-therapy PSA decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematopoietic progenitor cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Patients with Reactivation Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of specific Permanent Consequences e.g. diabetes insipidus (DI), growth hormone deficiency (GHD), neuropsychological impairment, etc.
Endpoint domain: Adverse events/effects
Primary endpoint: lung homogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Subjects With Serum Bactericidal Activity (hSBA) ≥ 1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor Ki-67 proliferation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Volume of gastric content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: composite variable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of acute graft-versus-host disease (GVHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of donor engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients acquiring MRSA
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With the Event Death
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Subjects Who Select Palliative Care Options
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Rate of complete or almost complete healing of visceral involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of complete or almost complete healing of skin involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: protein kinase C enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preservation of Inhibitory Effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Implant performance
Endpoint domain: Mortality/survival
Primary endpoint: Change in plasma blood glucose from fasting baseline value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma blood insulin from fasting baseline value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment-free remission (TFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major molecular remission (MMR/MR3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recommended Phase 2 Dose (RP2D)
Endpoint domain: Resource use
Primary endpoint: Maximum tolerated dose (MTD)
Endpoint domain: Resource use
Primary endpoint: Response rate assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neoplastic bile duct diagnosis confirmation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Balance capacities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait capacities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-minute walk test distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke or systemic embolism risk
Endpoint domain: Mortality/survival
Primary endpoint: Daily energy delivered from nutrition therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects with abnormal laboratory parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with abnormal vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with abnormal electrocardiogram
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with abnormal physical examination
Endpoint domain: Adverse events/effects
Primary endpoint: X-ray evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ultrasonography evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Verbal Analog Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adrenomedullin as a biomarker for pulmonary embolism diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cessation of spread or reduction in the size of the primary infection site lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IL-1β production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TNFα expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Caspase 1 (CASP1) expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of bowel entrapment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Wound healing effect (re-epithelization)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: safety of allogeneic EBV specific CTL
Endpoint domain: Adverse events/effects
Primary endpoint: persistence of allogeneic EBV specific CTL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline Average Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of Participants That Achieve Optimal PTA Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Technical Success of Use of UltraScore™ Focused Force PTA Balloon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increase in percentage of Treg cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of miRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OA-related joint pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in attitude towards sleep
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with a major adverse cardiovascular event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of ECG pattern distribution in LBBB patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with stress induced myocardial ischemia during Stress Magnetic resonance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with mechanical dyssynchrony evaluated with Echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change in the ISI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder pressure monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary Glucose Excretion 0-48 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Parental Vaccine Hesitancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral Feeding Readiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of lymph node metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cardiologic health status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anti-tissue transglutaminase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of metal contact allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Ceftaroline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of Ischaemic Voxels With an ADC<0.65 mm2/s
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean skinfold z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total interdental papilla formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PET/MR Scan Obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants With Confirmed Complete or Partial Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nadir Measurement for Absolute Neutrophil (ANC), White Blood Cell (WBC) and Platelet Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in 2h glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants that reach normoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Physical Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 25(OH)D Serum Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of JCAR017 in Peripheral Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and consistency of stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Patients With Prolonged Desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Glycosylated Hemoglobin (HbA1c) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success rate of ultrasound-guided thoracic epidural catheter insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Concentration of Creatine Kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Chair Rises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Squat Jump height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombotic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequencies of TFPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Parent's and Adolescent's Baseline Anxiety at 1 month
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Child's Baseline Anxiety at 1 month
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Parent's Baseline Feelings of Preparedness at 1 month
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Child's Baseline Feelings of Preparedness at 1 month
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cardiodynamic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient Oriented Eczema Measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dry Mouth assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hit ratio in a manual skill test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free basketball shots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standing jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Histopathology Endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients with adequate bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average of investigator's Major Symptom Score ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of osseous setting formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of clinical and laboratory adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: RBANS-H total score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area Under The Plasma Concentration Versus Time Curve (AUCt) of Plasma Total Molybdenum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicity of propranolol in association to cyclophosphamide
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive impairment alleviation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Endothelial shear stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in performance of movements with the paretic upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline on Cognitive Section of Alzheimer Disease Assessment Scale (ADAS-Cog)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of detection of liver metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Operative Time Savings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HEM concentration in seminal plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marijuana Use, Daily Dollar Averaged Over 7 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Stratified by Marijuana Abstinence Days Per Week
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: RAI Uptake and Tg Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in resting anal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported symptoms of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of complete and partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients free of biochemical recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Changes in maximal eccentric strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequencies of DLT and toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ES intensity between session 2 and 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activity as assessed by BOLD fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Visual Learning and Memory Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Global Neurocognitive effect as assessed by the Global Neurocognitive Assessment (GNA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Precipitated Withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With a ≥ 1 Point Improvement From Baseline in the Subject's Global Aesthetic Improvement Scale (GAIS) at Week 4
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants With a ≥ 1 Point Improvement From Baseline in the Physician's Global Aesthetic Improvement Scale (GAIS) at Week 4
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants a ≥1 Point Improvement From Baseline in the Physician's Mid-face Volume Deficit Scale (MFVDS) at Week 4
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of worked hours
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUC of Drospirenone and Ethinyl Estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeling guilty for being overweight
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Negative affectivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-control
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Difference in breath hydrogen concentration (BHC, ppm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnostic yield of TBNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of neutropenia grade 4 or fever
Endpoint domain: Adverse events/effects
Primary endpoint: Time to recovery (free of respiratory failure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composite performance measures for AF care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Modified Rankin Scale (mRS) Score of 0 or 1 at Day 90
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: change mean arterial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes